Skip to main content
TipRanks
Go Ultimate75% OFF

Xbrane Biopharma AB (7XB0) AI Stock Analysis

6 Followers
DE:7XB0

Xbrane Biopharma AB

(Frankfurt:7XB0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthStrong trailing-twelve-month revenue growth indicates that Xbrane is expanding commercial activity and gaining demand for its offerings. If sustained, this top-line progress can improve operating leverage, support investment in its pipeline, and strengthen its position in the biosimilar market.
Negative Factors
Persistent Net LossesThe return to a substantial trailing loss shows that revenue growth has not yet translated into sustainable earnings. Continued losses can limit internally funded investment, increase dependence on external capital, and make progress toward durable profitability more difficult.

Xbrane Biopharma AB (7XB0) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%125%DE:7XB0+33.05%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 19.62M
Dividend Yield
―
Average Volume (3M)
491
Price to Earnings (P/E)
-5.9
Beta (1Y)
1.14
Revenue Growth
-37.13%
EPS Growth
-119.85%
Country
Germany
Employees
28
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Xbrane Biopharma AB Business Overview & Revenue Model

Company Description

Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibi...

Xbrane Biopharma AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7XB0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA74OutperformSEK 360.89M1.8863.09%―――
SE:HNSASE:HNSA60NeutralSEK 4.82B-5.99――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:BINVSE:BINV49NeutralSEK 142.80M-0.29-128.54%―-83.67%-50.29%
SE:ELICSE:ELIC45NeutralSEK 162.84M-6.90-56.09%――14.10%
SE:ATORXSE:ATORX39UnderperformSEK 30.33M-0.01-439.98%―-99.33%64.90%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:7XB0SE:HNSASE:ATORXSE:BINVSE:ELICSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7XB0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7XB0Xbrane Biopharma AB0.950.2229.62%
SE:HNSAHansa Biopharma47.3219.3469.12%
SE:ATORXAlligator Bioscience AB0.01-0.16-94.29%
SE:BINVBioInvent International AB2.17-27.13-92.59%
SE:ELICElicera Therapeutics AB2.44-2.63-51.84%
SE:CANTACantargia AB1.28-1.89-59.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.